MADRIGAL PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $125.69 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-02-19
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was $125.69M, a 11.62% increase from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was $112.61M, a 89.36% increase from fiscal 2022.
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2022 was $59.47M, a 24.97% decline from fiscal 2021.
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2021 was $79.26M, a 195.27% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $125.69M 10-K · filed 2026-02-19 | |
| 2023-12-31 | $112.61M 10-K · filed 2026-02-19 | |
| 2022-12-31 | $59.47M 10-K · filed 2025-02-26 | |
| 2021-12-31 | $79.26M 10-K · filed 2024-02-28 | |
| 2020-12-31 | $26.84M 10-K/A · filed 2023-03-03 | $66.59M 10-K · filed 2021-02-25 |
| 2019-12-31 | $26.84M 10-K · filed 2022-02-24 | |
| 2018-12-31 | $17.53M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $2.88M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $9.75M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $1.99M 10-K · filed 2017-03-31 | $19.57M 10-K · filed 2016-03-15 |
| 2014-12-31 | $26.92M 10-K · filed 2016-03-15 | $26.92M 10-K · filed 2015-03-12 |
| 2013-12-31 | $29.88M 10-K · filed 2016-03-15 | |
| 2012-12-31 | $21.41M 10-K · filed 2015-03-12 | |
| 2011-12-31 | $16.44M 10-K · filed 2014-03-11 | |
| 2010-12-31 | $11.66M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |